Updated:
UCB Ventures
UCB Ventures is UCB's venture arm focused on supporting medical companies. It has made 28 investments, including a Series B investment in SpliceBio on June 11,...
UCB Ventures
UCB Ventures is UCB's venture arm focused on supporting medical companies. It has made 28 investments, including a Series B investment in SpliceBio on June 11, 2025. UCB Ventures has facilitated three portfolio exits, with Aetion exiting on May 15, 2025.
General information
Firm type
Venture Capital
Year founded
2017
Location
Region
Europe
Country
Belgium
City
Brussels
Corporate office
Brussels, Belgium
Sector focus
Frequently asked questions
Does UCB Ventures invest in therapeutics, digital health, or both?
UCB Ventures invests across both categories, provided the opportunity connects to the parent company's core immunology or neurology focus. Public portfolio evidence includes digital therapeutics, AI-powered drug discovery tools, and biomarker platforms. The firm does not invest in medical devices or health services unrelated to its therapeutic mandate.
Where does UCB Ventures source its deal flow?
Deal flow originates through the parent company's academic and clinical research networks, direct relationships with biotech accelerators, and co-investor syndicates across Europe and North America. Key geographic hubs include the Boston-Cambridge cluster, the San Francisco Bay Area, and the EU's major life-sciences innovation centers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: